STOCK TITAN

CeriBell, Inc. Financials

CBLL
Trailing 12 months to June 30, 2026
Revenue $102.0M +31.7% YoY
Net Income -$66.0M -33.6% YoY
EPS (Diluted) -$1.76 -83.3% YoY
Free Cash Flow -$54.7M -41.8% YoY
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD FYE December

CeriBell, Inc. (CBLL) reported $102.0M in revenue over the twelve months to Jun 30, 2026, up 31.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CBLL FY2025

High-margin growth is paired with persistent operating losses and cash needs funded outside operations.

Revenue nearly doubled from FY2023 to FY2025 while operating margin stayed near -60.0%, indicating that added volume has not yet produced fixed-cost absorption. In FY2025, operating cash flow of -$40.8M was close to net loss of -$53.4M; additional investing outflows made free cash flow even more negative, revealing a second cash demand beyond operating losses.

FY2024 financing cash flow reached $196.5M, while FY2025 liabilities were $40.5M versus equity of $155.3M. That combination points to an equity-heavy funding structure rather than a business financed primarily by debt, even as cumulative losses continued.

Gross margin widened from 84.4% in FY2023 to 87.9% in FY2025, but this improvement did not reach operating income. In FY2025, SG&A and R&D totaled $63.6M against $78.3M of gross profit, showing how operating costs absorb most gross profit before the bottom line.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 52 / 100
Financial Health Score 52/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of CeriBell, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
65
Dilution
6
R&D Intensity
42
Revenue Progress
83
Burn Trend
28
Balance Sheet
88
Altman Z-Score Safe
12.42

CeriBell, Inc. scores 12.42, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($910.7M) relative to total liabilities ($40.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
3/8

CeriBell, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing
N/A

CeriBell, Inc. reported a net loss of $53.4M while operations used $40.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

CeriBell, Inc. reported an operating loss of $58.4M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$89.1M
YoY+36.1%

CeriBell, Inc. generated $89.1M in revenue in fiscal year 2025. This represents an increase of 36.1% from the prior year.

EBITDA
-$57.1M
YoY-47.9%

CeriBell, Inc.'s EBITDA was -$57.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 47.9% from the prior year.

Net Income
-$53.4M
YoY-32.0%

CeriBell, Inc. reported -$53.4M in net income in fiscal year 2025. This represents a decrease of 32.0% from the prior year.

EPS (Diluted)
-$1.46

CeriBell, Inc. earned -$1.46 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
-$41.6M
YoY-14.3%

CeriBell, Inc. recorded an outflow of $41.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 14.3% from the prior year.

Cash & Debt
$40.5M
YoY-79.2%

CeriBell, Inc. held $40.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding
38M

CeriBell, Inc. had 38M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin
87.9%
YoY+1.2pp

CeriBell, Inc.'s gross margin was 87.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the prior year.

Operating Margin
-65.6%
YoY-4.9pp

CeriBell, Inc.'s operating margin was -65.6% in fiscal year 2025, reflecting core business profitability. This is down 4.9 percentage points from the prior year.

Net Margin
-60.0%
YoY+1.8pp

CeriBell, Inc.'s net profit margin was -60.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.8 percentage points from the prior year.

Return on Equity
-34.4%
YoY-13.2pp

CeriBell, Inc.'s ROE was -34.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 13.2 percentage points from the prior year.

Capital Allocation

R&D Spending
$19.1M
YoY+41.2%

CeriBell, Inc. invested $19.1M in research and development in fiscal year 2025. This represents an increase of 41.2% from the prior year.

Capital Expenditures
$767K
YoY-42.8%

CeriBell, Inc. invested $767K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 42.8% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

CBLL Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CBLL quarterly income statement
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Revenue$28.1M+6.1%$26.5M+6.9%$24.8M+9.7%$22.6M+6.6%$21.2M+3.5%$20.5M+10.6%$18.5M+7.8%$17.2M
Cost of Revenue$2.2M-36.0%$3.4M+7.4%$3.1M+18.7%$2.6M+5.2%$2.5M+1.3%$2.5M+8.2%$2.3M+5.1%$2.2M
Gross Profit$25.9M+12.2%$23.1M+6.8%$21.6M+8.5%$19.9M+6.7%$18.7M+3.7%$18.0M+10.9%$16.2M+8.2%$15.0M
R&D Expenses$6.7M+9.5%$6.2M+21.7%$5.1M+1.6%$5.0M+2.7%$4.9M+14.3%$4.2M+8.5%$3.9M+15.3%$3.4M
SG&A Expenses$14.8M-3.6%$15.3M+26.4%$12.1M+9.8%$11.0M-2.8%$11.4M+14.3%$9.9M-0.3%$10.0M+10.4%$9.0M
Operating Income-$20.0M+3.7%-$20.7M-42.1%-$14.6M+0.3%-$14.6M+2.0%-$15.0M-5.2%-$14.2M-10.3%-$12.9M-29.7%-$9.9M
Interest Expense$438K+0.9%$434K-6.1%$462K-3.8%$480K+0.6%$477K+1.3%$471K-5.6%$499K-5.8%$530K
Income Tax$0N/AN/AN/A$0N/AN/AN/A
Net Income-$19.3M+2.4%-$19.7M-45.9%-$13.5M-0.5%-$13.5M+1.3%-$13.6M-6.8%-$12.8M-1.6%-$12.6M-20.7%-$10.4M
EPS (Diluted)-$0.51+1.9%-$0.52-44.4%-$0.36+2.7%-$0.37+2.6%-$0.38-5.6%-$0.36-122.1%$1.63+188.1%-$1.85

CBLL Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CBLL quarterly balance sheet
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Total Assets$166.3M-6.6%$178.1M-9.1%$195.8M-1.9%$199.5M-3.9%$207.7M-2.7%$213.5M-5.3%$225.4M+379.0%$47.1M
Current Assets$157.8M-6.6%$168.9M-9.5%$186.7M-2.7%$191.8M-4.0%$199.8M-2.7%$205.4M-5.5%$217.3M+521.5%$35.0M
Cash & Equivalents$32.7M-27.8%$45.3M+11.8%$40.5M+70.5%$23.7M-40.9%$40.1M-73.8%$153.4M-21.1%$194.4M+1277.5%$14.1M
Inventory$6.7M-2.4%$6.9M-5.3%$7.3M+21.0%$6.0M+0.4%$6.0M-8.4%$6.6M-5.5%$6.9M+0.4%$6.9M
Accounts Receivable$16.0M+1.8%$15.7M+4.4%$15.1M+23.0%$12.2M-0.6%$12.3M+9.0%$11.3M+3.9%$10.9M+9.1%$10.0M
Total Liabilities$38.0M+2.1%$37.3M-7.9%$40.5M+14.2%$35.4M-0.3%$35.5M+9.0%$32.6M-4.8%$34.2M-81.3%$183.0M
Current Liabilities$17.2M+6.3%$16.2M-15.7%$19.2M+26.5%$15.2M+1.0%$15.0M+26.9%$11.8M-8.9%$13.0M-0.8%$13.1M
Total Equity$128.3M-8.9%$140.8M-9.3%$155.3M-5.3%$164.1M-4.7%$172.2M-4.8%$180.9M-5.4%$191.2M+240.6%-$136.0M
Retained Earnings-$259.4M-8.0%-$240.1M-9.0%-$220.4M-6.5%-$206.8M-7.0%-$193.4M-7.6%-$179.7M-7.7%-$166.9M-8.1%-$154.4M

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

CBLL Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CBLL quarterly cash flow statement
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Operating Cash Flow-$12.9M+33.3%-$19.3M-79.1%-$10.8M+2.9%-$11.1M-47.3%-$7.5M+33.9%-$11.4M-14.3%-$10.0M-16.8%-$8.5M
Capital Expenditures$17K-86.4%$125K-30.2%$179K-51.5%$369K+419.7%$71K-52.0%$148K-58.5%$357K-37.0%$567K
Free Cash Flow-$12.9M+33.7%-$19.4M-77.3%-$11.0M+4.5%-$11.5M-50.8%-$7.6M+34.2%-$11.6M-11.8%-$10.3M-13.4%-$9.1M
Investing Cash Flow-$606K-102.7%$22.4M-14.0%$26.1M+476.0%-$6.9M+93.6%-$107.7M-263.7%-$29.6M-5905.9%-$493K-369.4%$183K
Financing Cash Flow$880K-46.1%$1.6M+16.3%$1.4M-14.5%$1.6M-18.2%$2.0M+100200.0%$2K-100.0%$190.7M+10202.1%-$1.9M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CBLL Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

CBLL quarterly financial ratios
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Gross Margin92.3%+5.0pp87.3%-0.1pp87.3%-1.0pp88.3%+0.2pp88.1%+0.2pp87.9%+0.3pp87.6%+0.3pp87.3%
Operating Margin-71.1%+7.2pp-78.3%-19.4pp-58.9%+5.9pp-64.8%+5.7pp-70.5%-1.2pp-69.3%+0.2pp-69.5%-11.7pp-57.8%
Net Margin-68.6%+5.9pp-74.5%-19.9pp-54.6%+5.0pp-59.6%+4.7pp-64.4%-2.0pp-62.4%+5.5pp-67.8%-7.3pp-60.6%
Return on Equity-15.0%-1.0pp-14.0%-5.3pp-8.7%-0.5pp-8.2%-0.3pp-7.9%-0.9pp-7.1%-0.5pp-6.6%N/A
Return on Assets-11.6%-0.5pp-11.1%-4.2pp-6.9%-0.2pp-6.8%-0.2pp-6.6%-0.6pp-6.0%-0.4pp-5.6%+16.6pp-22.1%
Current Ratio9.18-1.3x10.44+0.7x9.73-2.9x12.65-0.7x13.31-4.1x17.36+0.6x16.73+14.1x2.67
Debt-to-Equity0.300.0x0.260.0x0.260.0x0.220.0x0.210.0x0.180.0x0.18N/A
FCF Margin-45.8%+27.5pp-73.3%-29.1pp-44.2%+6.6pp-50.8%-14.9pp-35.9%+20.5pp-56.4%-0.6pp-55.8%-2.8pp-53.0%

Similar Companies

Frequently Asked Questions

What is CeriBell, Inc.'s annual revenue?

CeriBell, Inc. (CBLL) reported $89.1M in total revenue for fiscal year 2025. This represents a 36.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is CeriBell, Inc.'s revenue growing?

CeriBell, Inc. (CBLL) revenue grew by 36.1% year-over-year, from $65.4M to $89.1M in fiscal year 2025.

Is CeriBell, Inc. profitable?

No, CeriBell, Inc. (CBLL) reported a net income of -$53.4M in fiscal year 2025, with a net profit margin of -60.0%.

CeriBell, Inc. (CBLL) reported diluted earnings per share of -$1.46 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CeriBell, Inc. (CBLL) had EBITDA of -$57.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

CeriBell, Inc. (CBLL) had a gross margin of 87.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

CeriBell, Inc. (CBLL) had an operating margin of -65.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

CeriBell, Inc. (CBLL) had a net profit margin of -60.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

CeriBell, Inc. (CBLL) has a return on equity of -34.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

CeriBell, Inc. (CBLL) recorded an outflow of $41.6M in free cash flow during fiscal year 2025. This represents a -14.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

CeriBell, Inc. (CBLL) recorded an outflow of $40.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

CeriBell, Inc. (CBLL) had $195.8M in total assets as of fiscal year 2025, including both current and long-term assets.

CeriBell, Inc. (CBLL) invested $767K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

CeriBell, Inc. (CBLL) invested $19.1M in research and development during fiscal year 2025.

CeriBell, Inc. (CBLL) had 38M shares outstanding as of fiscal year 2025.

CeriBell, Inc. (CBLL) had a current ratio of 9.73 as of fiscal year 2025, which is generally considered healthy.

CeriBell, Inc. (CBLL) had a debt-to-equity ratio of 0.26 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

CeriBell, Inc. (CBLL) had a return on assets of -27.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

At the end of fiscal year 2025, CeriBell, Inc. (CBLL) held $159.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $40.8M over that year. Dividing the one by the other, the reported balance equals about 47 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

CeriBell, Inc. (CBLL) has an Altman Z-Score of 12.42, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

CeriBell, Inc. (CBLL) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

CeriBell, Inc. (CBLL) reported a net loss of $53.4M while operations used $40.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

CeriBell, Inc. (CBLL) reported an operating loss of $58.4M against $1.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

CeriBell, Inc. (CBLL) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top